CY1122534T1 - Νεες ενωσεις μεθυλο-πιπεριδινης χρησιμες για την αναστολη της μ1κροσωμικης συνθετασης-1 της προσταγλανδινης ε2 - Google Patents
Νεες ενωσεις μεθυλο-πιπεριδινης χρησιμες για την αναστολη της μ1κροσωμικης συνθετασης-1 της προσταγλανδινης ε2Info
- Publication number
- CY1122534T1 CY1122534T1 CY20201100076T CY201100076T CY1122534T1 CY 1122534 T1 CY1122534 T1 CY 1122534T1 CY 20201100076 T CY20201100076 T CY 20201100076T CY 201100076 T CY201100076 T CY 201100076T CY 1122534 T1 CY1122534 T1 CY 1122534T1
- Authority
- CY
- Cyprus
- Prior art keywords
- prostaglandin
- inhibition
- synthesis
- compounds useful
- piperidine compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει ενώσεις με Τύπο (1), ή ένα φαρμακευτικά αποδεκτό άλας αυτών, τον τύπο (1), όπου τα R, R1 και G είναι όπως περιγράφονται στην παρούσα• μεθόδους για την παρασκευή των ενώσεων• και χρήση των ενώσεων για τη θεραπεία του πόνου και/ή της φλεγμονής που σχετίζεται με την αρθρίτιδα ή την οστεοαρθρίτιδα.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462072196P | 2014-10-29 | 2014-10-29 | |
| PCT/US2015/056960 WO2016069376A1 (en) | 2014-10-29 | 2015-10-22 | Novel methyl-piperidine compounds useful for inhibiting microsomal prostaglandin e2 synthase-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122534T1 true CY1122534T1 (el) | 2021-01-27 |
Family
ID=54478248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100076T CY1122534T1 (el) | 2014-10-29 | 2020-01-29 | Νεες ενωσεις μεθυλο-πιπεριδινης χρησιμες για την αναστολη της μ1κροσωμικης συνθετασης-1 της προσταγλανδινης ε2 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9962375B2 (el) |
| EP (1) | EP3230278B1 (el) |
| JP (1) | JP6393830B2 (el) |
| KR (1) | KR101898829B1 (el) |
| CN (1) | CN107074829B (el) |
| AR (1) | AR102362A1 (el) |
| AU (1) | AU2015339644B2 (el) |
| CA (1) | CA2963321C (el) |
| CL (1) | CL2017001017A1 (el) |
| CY (1) | CY1122534T1 (el) |
| DK (1) | DK3230278T3 (el) |
| EA (1) | EA032428B1 (el) |
| ES (1) | ES2773439T3 (el) |
| HR (1) | HRP20200216T1 (el) |
| HU (1) | HUE047895T2 (el) |
| JO (1) | JO3581B1 (el) |
| LT (1) | LT3230278T (el) |
| MX (1) | MX2017005659A (el) |
| NZ (1) | NZ730724A (el) |
| PL (1) | PL3230278T3 (el) |
| PT (1) | PT3230278T (el) |
| RS (1) | RS59783B1 (el) |
| SI (1) | SI3230278T1 (el) |
| TW (1) | TWI605039B (el) |
| WO (1) | WO2016069376A1 (el) |
| ZA (1) | ZA201702198B (el) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201627299A (zh) | 2014-10-29 | 2016-08-01 | 美國禮來大藥廠 | 用於抑制微粒體前列腺素ｅ合成酶１之新穎羧酸化合物 |
| EP3737370A4 (en) * | 2018-01-09 | 2021-12-15 | Brigham Young University | COMPOSITIONS AND METHODS OF PAIN TREATMENT WITH WOGONIN |
| CN108558806B (zh) * | 2018-05-31 | 2020-04-17 | 南京药石科技股份有限公司 | 一种5-氧代-四氢吡喃-3-羧酸酯的关键中间体及其制备方法 |
| WO2020061475A2 (en) * | 2018-09-21 | 2020-03-26 | The Johns Hopkins University | Compositions and methods for treating metabolic disorders |
| BR112021026376A2 (pt) | 2019-06-25 | 2022-05-10 | Gilead Sciences Inc | Proteínas de fusão flt3l-fc e métodos de uso |
| PL4045083T3 (pl) | 2019-10-18 | 2024-05-13 | Forty Seven, Inc. | Terapie skojarzone do leczenia zespołów mielodysplastycznych i ostrej białaczki szpikowej |
| MX2022005123A (es) | 2019-10-31 | 2022-05-30 | Forty Seven Inc | Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico. |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| AU2020412875A1 (en) | 2019-12-24 | 2022-06-23 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
| AU2021219668A1 (en) | 2020-02-14 | 2022-08-25 | Gilead Sciences, Inc. | Antibodies and fusion proteins that bind to CCR8 and uses thereof |
| MX2022013619A (es) | 2020-05-01 | 2022-11-16 | Gilead Sciences Inc | Compuestos de 2,4-dioxopirimidina que inhiben cd73. |
| TW202211917A (zh) * | 2020-08-21 | 2022-04-01 | 南韓商治納輔醫藥科技有限公司 | 對前列腺素e2受體具有抑制活性的新穎化合物及其用途 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4359389A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| TW202330504A (zh) | 2021-10-28 | 2023-08-01 | 美商基利科學股份有限公司 | 嗒𠯤—３（２ｈ）—酮衍生物 |
| WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| US20230242508A1 (en) | 2021-12-22 | 2023-08-03 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| US20230373950A1 (en) | 2022-03-17 | 2023-11-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023183817A1 (en) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Ｋｒａｓ ｇ１２ｄ調節化合物 |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6355010B1 (en) * | 1999-03-31 | 2002-03-12 | Coaxia, Inc. | Intravascular spinal perfusion and cooling for use during aortic surgery |
| EP1627869B1 (en) * | 2003-05-20 | 2012-05-02 | Ajinomoto Co., Inc. | Vanilloid receptor modulators |
| US20050239921A1 (en) * | 2004-04-27 | 2005-10-27 | Birmingham John N | Preparation of organic additive-treated, pyrogenic silica-encapsulated titanium dioxide particles |
| UY32470A (es) * | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
| WO2011023812A1 (en) * | 2009-08-27 | 2011-03-03 | Novasaid Ab | Microsomal prostaglandin e synthase-1 (mpges1) inhibitors |
| JP5579862B2 (ja) * | 2009-10-23 | 2014-08-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ミクロソームプロスタグランジンｅ２シンターゼ−１のインヒビター |
| WO2013146970A1 (ja) * | 2012-03-29 | 2013-10-03 | 第一三共株式会社 | 新規キノリン誘導体 |
| CA2916101A1 (en) * | 2013-06-20 | 2014-12-24 | Novasaid Ab | Piperidinyl benzoimidazole derivatives as mpge-1 inhibitors |
| TW201627299A (zh) | 2014-10-29 | 2016-08-01 | 美國禮來大藥廠 | 用於抑制微粒體前列腺素ｅ合成酶１之新穎羧酸化合物 |
-
2015
- 2015-10-18 JO JOP/2015/0256A patent/JO3581B1/ar active
- 2015-10-19 TW TW104134250A patent/TWI605039B/zh active
- 2015-10-19 AR ARP150103382A patent/AR102362A1/es unknown
- 2015-10-22 WO PCT/US2015/056960 patent/WO2016069376A1/en active Application Filing
- 2015-10-22 JP JP2017522866A patent/JP6393830B2/ja active Active
- 2015-10-22 EP EP15791432.6A patent/EP3230278B1/en active Active
- 2015-10-22 NZ NZ730724A patent/NZ730724A/en unknown
- 2015-10-22 EA EA201790766A patent/EA032428B1/ru not_active IP Right Cessation
- 2015-10-22 KR KR1020177011303A patent/KR101898829B1/ko active IP Right Grant
- 2015-10-22 ES ES15791432T patent/ES2773439T3/es active Active
- 2015-10-22 CN CN201580058595.9A patent/CN107074829B/zh active Active
- 2015-10-22 SI SI201531036T patent/SI3230278T1/sl unknown
- 2015-10-22 PT PT157914326T patent/PT3230278T/pt unknown
- 2015-10-22 CA CA2963321A patent/CA2963321C/en active Active
- 2015-10-22 PL PL15791432T patent/PL3230278T3/pl unknown
- 2015-10-22 RS RS20200015A patent/RS59783B1/sr unknown
- 2015-10-22 AU AU2015339644A patent/AU2015339644B2/en active Active
- 2015-10-22 US US15/520,462 patent/US9962375B2/en active Active
- 2015-10-22 MX MX2017005659A patent/MX2017005659A/es active IP Right Grant
- 2015-10-22 HU HUE15791432A patent/HUE047895T2/hu unknown
- 2015-10-22 DK DK15791432.6T patent/DK3230278T3/da active
- 2015-10-22 LT LTEP15791432.6T patent/LT3230278T/lt unknown
-
2017
- 2017-03-29 ZA ZA2017/02198A patent/ZA201702198B/en unknown
- 2017-04-24 CL CL2017001017A patent/CL2017001017A1/es unknown
-
2018
- 2018-05-07 US US15/972,699 patent/US20180250282A1/en not_active Abandoned
-
2020
- 2020-01-29 CY CY20201100076T patent/CY1122534T1/el unknown
- 2020-02-11 HR HRP20200216TT patent/HRP20200216T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122534T1 (el) | Νεες ενωσεις μεθυλο-πιπεριδινης χρησιμες για την αναστολη της μ1κροσωμικης συνθετασης-1 της προσταγλανδινης ε2 | |
| CY1122279T1 (el) | Ενωσεις ναφθυριδινης αναστολεις κινασης jak | |
| CY1124496T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
| CY1123417T1 (el) | Παραγωγα τετρα�δροϊσοκινολινης | |
| CY1121047T1 (el) | Ενωσεις αμιδιου για τη θεραπεια toy hiv | |
| CY1123994T1 (el) | Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4 | |
| CY1120273T1 (el) | Συνθεσεις και μεθοδοι για την τροποποιηση φαρνεσοειδων υποδοχεων χ | |
| CY1119531T1 (el) | Ενωσεις και συνθεσεις για την ρυθμιση της δραστηριοτητας toy egfr | |
| CY1123475T1 (el) | Αναστολεις της ειδικης για λυσινη απομεθυλασης-1 | |
| CY1124368T1 (el) | Μεθοδοι αυξησης της τονικης αναστολης και θεραπειας του συνδρομου angelman | |
| CY1123906T1 (el) | Αναστολεις απομεθυλασης ιστονης | |
| CY1124620T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
| CL2017001050A1 (es) | Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| CY1119134T1 (el) | Υποδοχεις της νεπριλυσινης | |
| CR20140548A (es) | Derivados de aril-sultamo como moduladores de rorc | |
| CY1121602T1 (el) | Συνθεση της κοπανλισιμπης και του διυδροχλωρικου αλατος της | |
| CY1121746T1 (el) | Αναστολεις mgat2 τετραζολονο-υποκατεστημενης διυδροπυριδινονης | |
| CY1120420T1 (el) | Παραγωγα σουλφονυλοπιπεριδινης και χρηση αυτων πα την αγωγη νοσων με τη μεσολαβηση προκινετισινης | |
| CY1124933T1 (el) | Κυτταροτοξικες και αντι-μιτωτικες ενωσεις και μεθοδοι χρησης αυτων | |
| PH12017500095A1 (en) | Imidazopyridazine compounds | |
| CY1120836T1 (el) | Ενωσεις 1,3,4-θειαδιαζοαης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| MX2016015247A (es) | Derivados de benceno-sulfonamida y su uso como moduladores del receptor c huerfano relacionado a acido retinoico (rorc). | |
| BR112018068412A2 (pt) | composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral | |
| CY1121650T1 (el) | Αναστολεις συνθασης αλδοστερονης | |
| CY1122439T1 (el) | Κυκλοαλκυλ-συνδεδεμενα παραγωγα δι-ετεροκυκλων |